aarsd1 Antibody

What is AARSD1 and what is its primary biological function?

AARSD1, also known as alanyl-tRNA editing protein, belongs to the class-II aminoacyl-tRNA synthetase family. It plays a crucial role in protein synthesis by functioning in trans to edit the amino acid moiety from incorrectly charged tRNA(Ala) . AARSD1 is involved in the regulation of translational fidelity and alanyl-tRNA aminoacylation processes . The protein has three known isoforms produced by alternative splicing in humans and is primarily located in the cytoplasm with some nuclear presence . The biological importance of AARSD1 stems from its fundamental role in maintaining the accuracy of protein synthesis by ensuring that only correctly charged tRNA molecules participate in translation.

What are the validated applications for AARSD1 antibodies in research?

AARSD1 antibodies have been validated for multiple experimental applications, primarily Western blot (WB), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry (IHC) . For Western blotting, the antibody typically detects a band at approximately 46 kDa in human cell lines such as HeLa and U251 . In immunohistochemistry, AARSD1 antibodies have been successfully used on paraffin-embedded human tissues including testis and lung cancer samples . The recommended dilutions vary by application: 1:500-1:2000 for Western blot, 1:2000-1:10000 for ELISA, and 1:20-1:200 for IHC . When selecting an AARSD1 antibody for a specific application, it's essential to choose one that has been validated for that particular method to ensure reliable results.

How do recombinant antibodies for AARSD1 differ from traditional polyclonal antibodies?

Recombinant antibodies represent an advancement over traditional polyclonal antibodies for studying aminoacyl-tRNA synthetases like AARSD1. Recombinant antibodies are generated through phage display selections using synthetic human single-chain fragment variable (scFv) libraries . This approach yields high-affinity antibodies with several advantages: they provide consistent performance between batches, offer higher specificity, and their sequences can be deposited in publicly available databases for reproducibility . In contrast, traditional polyclonal antibodies like AARSD1 Polyclonal Antibody (PAC040482) are generated in animals (typically rabbits) immunized with recombinant protein fragments . While polyclonal antibodies recognize multiple epitopes on the target protein, potentially increasing sensitivity, they may exhibit batch-to-batch variation and potentially higher cross-reactivity. For critical research applications requiring high reproducibility, recombinant antibodies may be preferable despite their generally higher cost.

What are the optimal conditions for using AARSD1 antibody in Western blotting?

For optimal Western blot results with AARSD1 antibody, researchers should follow these methodological considerations:

• Sample preparation: Use whole cell lysates from human cell lines (HeLa and U251 have been validated) .

• Concentration: Use AARSD1 antibody at approximately 0.8μg/ml concentration .

• Dilution range: The recommended working dilution is 1:500-1:2000 .

• Secondary antibody: Use goat polyclonal to rabbit IgG at 1/10000 dilution for detection .

• Expected bands: Look for a primary band at approximately 46 kDa, though predicted bands may also appear at 59 and 66 kDa depending on the isoform .

• Controls: Include positive control lysates from cell lines known to express AARSD1 and negative controls where appropriate.

• Storage conditions: Store the antibody at -20°C in the provided buffer (50% Glycerol, 0.01M PBS, pH 7.4 with 0.03% Proclin 300 as preservative) .

Proper optimization of antibody concentration is crucial, as too high concentrations may lead to background issues, while too low concentrations might result in weak signal.

How can researchers effectively validate the specificity of AARSD1 antibodies?

Validating antibody specificity is critical for reliable experimental outcomes. For AARSD1 antibodies, a multi-assay validation approach is recommended:

• ELISA screening: Initial screening to confirm binding to the purified antigen .

• Homogenous time resolved fluorescence (HTRF): Secondary confirmation of binding activity .

• Suspension bead assay: Test specificity against the target and potential cross-reactants. For example, in one study, antibodies were tested against their target aaRS as well as all other produced aaRS antigens to ensure no cross-reactivity .

• Western blot validation: Verify the antibody detects a protein of the expected molecular weight.

• Immunoprecipitation followed by mass spectrometry (IP-MS): Gold standard validation to confirm the antibody captures the endogenous protein from cell lysates .

• Immunofluorescence: Confirm appropriate subcellular localization patterns .

• Knockout/knockdown validation: Test on samples where AARSD1 has been depleted to confirm signal specificity.

This comprehensive validation approach ensures that observed signals truly represent AARSD1 rather than non-specific interactions.

What considerations should be made when using AARSD1 antibodies for immunohistochemistry?

When using AARSD1 antibodies for immunohistochemistry (IHC), researchers should consider the following methodological aspects:

• Tissue processing: Use paraffin-embedded tissues that have been properly fixed and processed .

• Antigen retrieval: Optimize antigen retrieval methods (heat or enzymatic) to expose epitopes potentially masked during fixation.

• Antibody dilution: Start with the recommended dilution range of 1:20-1:200 and optimize for your specific tissue samples .

• Incubation conditions: Determine optimal temperature, time, and buffer conditions.

• Detection system: Select an appropriate detection system compatible with rabbit primary antibodies.

• Controls: Include positive control tissues (testis and lung cancer tissues have been successfully used) , as well as negative controls (omitting primary antibody).

• Background reduction: If background is problematic, consider blocking steps with normal serum or protein blockers.

• Signal interpretation: Be aware that AARSD1 is primarily cytoplasmic with some nuclear localization.

Optimization is particularly important for IHC as tissue type, fixation methods, and processing can significantly affect antibody performance.

How can AARSD1 antibodies be applied to investigate protein-protein interactions?

Investigating AARSD1's protein-protein interactions requires sophisticated approaches:

• Immunoprecipitation-Mass Spectrometry (IP-MS): High-quality AARSD1 antibodies can capture endogenous AARSD1 and its interacting partners for identification by mass spectrometry . This approach has been successful for other aminoacyl-tRNA synthetases in identifying complex formation and unexpected binding partners.

• Co-immunoprecipitation (Co-IP): Use AARSD1 antibodies to pull down the protein complex and blot for suspected interaction partners.

• Proximity Ligation Assay (PLA): This technique can visualize protein-protein interactions in situ by generating fluorescent signals only when two proteins are in close proximity.

• Cross-linking studies: Chemical cross-linking followed by immunoprecipitation with AARSD1 antibodies can stabilize transient interactions.

• Multi-tRNA synthetase complex analysis: While AARSD1 is not known to be part of the multi-tRNA synthetase complex (MSC), similar methodologies to those used for studying MSC components could be applied .

The specificity of the antibody is crucial for these applications, as non-specific interactions can lead to false positives. Validation through reciprocal immunoprecipitation (using antibodies against the suspected interaction partners) can provide additional confidence in the results.

What approaches can be used to study noncanonical functions of AARSD1?

Aminoacyl-tRNA synthetases, including AARSD1, are increasingly recognized for their noncanonical functions beyond protein translation. To investigate these functions:

• Subcellular localization studies: Use immunofluorescence with validated AARSD1 antibodies to track potential relocalization under different cellular conditions or stimuli .

• Protein domain mapping: Generate antibodies against specific domains of AARSD1 to distinguish which regions are involved in canonical versus noncanonical functions .

• Conditional knockout/knockdown systems: Create cellular systems where AARSD1 can be depleted at specific times or in specific compartments to observe phenotypic effects.

• Secretion analysis: Investigate whether AARSD1 is secreted extracellularly under certain conditions, as has been observed with other aaRSs .

• Post-translational modification analysis: Use immunoprecipitation with AARSD1 antibodies followed by mass spectrometry to identify potential regulatory modifications.

• Disease model systems: Explore AARSD1 behavior in cellular or animal models of neurodegenerative disorders or cancer, where dysregulation has been implicated .

These approaches can help uncover unexpected roles of AARSD1 beyond its established function in tRNA editing.

How does AARSD1 expression and function vary across different cell types and disease states?

Understanding AARSD1's expression patterns across different contexts provides valuable research insights:

• Comparative expression analysis: Use validated AARSD1 antibodies for Western blot or IHC to compare expression levels across normal tissues, cancer samples, and diseased tissues.

• Single-cell analysis: Employ immunofluorescence to examine cell-to-cell variability in AARSD1 expression within heterogeneous tissues.

• Disease correlation studies: Correlate AARSD1 expression levels with disease progression markers in conditions where it may play a role, such as neurodegenerative disorders or cancer .

• Functional impact assessment: Use cellular models with modified AARSD1 expression to determine how changes affect cellular phenotypes in different cell types.

• Biomarker potential evaluation: Assess whether AARSD1 levels or modifications could serve as diagnostic or prognostic markers in specific diseases.

While some aminoacyl-tRNA synthetases have been associated with specific autoimmune conditions, particularly antisynthetase syndrome , the specific involvement of AARSD1 in autoimmunity needs further investigation. Researchers should consider both total expression levels and potential alterations in subcellular localization when studying AARSD1 in disease contexts.

What are common issues when using AARSD1 antibodies and how can they be resolved?

Researchers may encounter several challenges when working with AARSD1 antibodies:

When troubleshooting, it's important to remember that antibody performance can be highly dependent on the specific experimental conditions and sample types.

How can researchers interpret apparent discrepancies in AARSD1 detection across different experimental platforms?

When faced with discrepancies in AARSD1 detection:

• Epitope accessibility: Different experimental conditions may affect epitope exposure. For example, an antibody that works well in Western blot might fail in IHC due to epitope masking during fixation .

• Isoform specificity: Consider whether your antibody targets all three known AARSD1 isoforms or only specific ones .

• Post-translational modifications: PTMs might mask epitopes in certain contexts or alter protein mobility in gels.

• Complexes vs. free protein: Some antibodies may preferentially detect free AARSD1 versus AARSD1 in protein complexes, similar to what has been observed with other aaRSs and the multi-tRNA synthetase complex .

• Antibody validation depth: Assess whether the antibody has been validated for your specific application. For instance, some antibodies show excellent performance in Western blot but poor results in immunoprecipitation despite favorable off-rates .

• Quantitative limitations: Remember that techniques like mass spectrometry used in IP-MS aren't inherently quantitative without proper controls and calibration .

When interpreting discrepancies, consider using complementary techniques and multiple antibodies targeting different epitopes to build a more complete picture of AARSD1 biology.

What factors should be considered when analyzing AARSD1 in complex biological samples?

Analyzing AARSD1 in complex samples requires careful consideration of several factors:

• Sample preparation impact: Different lysis buffers and extraction methods may yield varying amounts of AARSD1, especially if it participates in protein complexes or associates with cellular structures.

• Normalization approach: Choose appropriate loading controls or normalization methods based on your experimental question. For instance, if investigating AARSD1 in cancer, common housekeeping proteins might be dysregulated.

• Cross-reactivity assessment: Even highly specific antibodies may exhibit unexpected cross-reactivity in complex samples. Verify specificity through knockout/knockdown controls when possible.

• Context-dependent modifications: Consider that AARSD1 may undergo context-specific post-translational modifications that affect antibody recognition or protein function.

• Signal quantification methods: When quantifying AARSD1 signals, be aware of the limitations of your detection method (colorimetric, chemiluminescent, fluorescent) and ensure you're working within the linear range.

• Comparative analysis: When comparing AARSD1 levels between conditions, process and analyze all samples simultaneously to minimize technical variation.

These considerations help ensure robust and reproducible analysis of AARSD1 in complex biological contexts.

How is AARSD1 dysregulation implicated in disease pathogenesis?

AARSD1 dysregulation has been implicated in several disease processes:

• Cancer: AARSD1 appears to play a role in cancer biology, with immunohistochemistry studies showing its presence in lung cancer tissues . While the exact mechanisms remain under investigation, its fundamental role in protein synthesis accuracy suggests that dysregulation could contribute to the altered proteome characteristic of cancer cells.

• Neurodegenerative disorders: Dysregulation of AARSD1 has been linked to neurodegenerative conditions . This connection likely stems from the critical importance of translational fidelity in neurons, where protein misfolding and aggregation are key pathological processes.

• Potential autoimmune connections: While AARSD1-specific autoantibodies have not been directly reported in the literature, other aminoacyl-tRNA synthetases are known autoantigens in idiopathic inflammatory myopathies and antisynthetase syndrome . This raises the possibility that AARSD1 might also play a role in autoimmune contexts.

• Translational fidelity disorders: As AARSD1 functions in editing incorrectly charged tRNA(Ala) , its dysfunction could theoretically lead to mistranslation and protein misfolding diseases.

The investigation of AARSD1 in disease contexts is still evolving, and high-quality antibodies are essential tools for further elucidating these connections.

What is the relationship between aminoacyl-tRNA synthetases and autoimmune diseases?

Aminoacyl-tRNA synthetases have significant connections to autoimmunity:

• Antisynthetase syndrome: This is a subgroup of idiopathic inflammatory myopathies (IIMs) characterized by circulating autoantibodies against aminoacyl-tRNA synthetases . Eight different aaRSs have been identified as autoantigens in this condition .

• Histidyl-tRNA synthetase (HisRS) as a major autoantigen: HisRS represents the primary autoantigen in these diseases, with autoantibodies against it reported in 20-30% of IIM patients .

• Extracellular presence: Some aaRSs have been detected in circulation, suggesting potential immunomodulatory roles beyond their canonical functions . This extracellular presence may contribute to their role as autoantigens.

• Potential mechanisms: While the exact mechanisms underlying aaRS autoimmunity remain under investigation, possible factors include:

  • Release of aaRSs during cell damage or stress

  • Structural similarities to microbial proteins (molecular mimicry)

  • Post-translational modifications creating neo-epitopes

While AARSD1-specific autoantibodies have not been explicitly reported in the available literature, the established connection between other aaRSs and autoimmunity suggests this could be an area for future investigation.

How can AARSD1 research inform potential therapeutic strategies?

AARSD1 research offers several avenues for therapeutic development:

• Target for cancer therapy: Given its apparent role in cancer, particularly lung cancer , AARSD1 could represent a novel therapeutic target. Selective inhibition might disrupt cancer cell protein synthesis without significantly affecting normal cells if cancer cells show dependence on AARSD1 function.

• Biomarker development: AARSD1 expression or modification patterns might serve as diagnostic or prognostic biomarkers in conditions where its dysregulation occurs. High-quality antibodies are essential for developing such applications.

• Structure-based drug design: Understanding AARSD1's structure and function can inform the design of small molecule modulators to correct dysregulation in disease states.

• Gene therapy approaches: For conditions where AARSD1 deficiency contributes to pathology, gene therapy strategies could be explored to restore normal levels.

• Immunomodulatory strategies: If AARSD1 proves to be involved in autoimmune processes (similar to other aaRSs), targeted immunotherapies could be developed.

The development of well-validated research tools, including specific antibodies and recombinant proteins, is accelerating research in this field and may lead to novel therapeutic approaches in the coming years .

What emerging technologies can enhance AARSD1 antibody applications in research?

Several cutting-edge technologies are poised to expand AARSD1 antibody applications:

• Single-cell proteomics: Combining AARSD1 antibodies with single-cell analysis techniques can reveal cell-to-cell variation in expression and localization.

• Intrabodies: Engineering AARSD1 antibodies as intrabodies (intracellular antibodies) could allow real-time tracking of AARSD1 dynamics in living cells.

• Nanobodies and small format antibodies: These smaller antibody fragments offer advantages for certain applications, including superior tissue penetration and access to sterically hindered epitopes.

• Proximity labeling: Antibody-guided proximity labeling approaches can identify novel AARSD1 interaction partners in their native cellular environment.

• Spatially resolved proteomics: Techniques like imaging mass cytometry combined with AARSD1 antibodies can map expression patterns within tissue architecture.

These technologies, coupled with ongoing improvements in antibody engineering and validation methodologies, promise to deepen our understanding of AARSD1 biology in normal and disease states.

What are the key unanswered questions regarding AARSD1 biology?

Despite progress in AARSD1 research, several fundamental questions remain:

• Regulatory mechanisms: How is AARSD1 expression and activity regulated in different cellular contexts?

• Noncanonical functions: Does AARSD1 possess additional functions beyond its established role in tRNA editing, similar to other aminoacyl-tRNA synthetases?

• Disease mechanisms: What are the precise mechanisms by which AARSD1 dysregulation contributes to neurodegenerative disorders and cancer?

• Structural insights: How does the three-dimensional structure of AARSD1 contribute to its function and potential interactions?

• Evolutionary conservation: How conserved is AARSD1 function across species, and what does this tell us about its fundamental importance?

• Therapeutic potential: Can AARSD1 be effectively targeted for therapeutic intervention in relevant disease states?

Addressing these questions will require continued development and refinement of research tools, including highly specific antibodies capable of distinguishing between AARSD1 isoforms and modified forms.